Access to health care services 2007 Report
A SA Human Rights Commission report on access to health care services from 2007.
SANCDA Call to action: NCDs stakeholder meeting report 2014
SA NCDs Stakeholders Meeting Report June 2014 – Compressed 1mb with hyperlinks
Delivering NCDs medicines access CCMDD
After 7 years the government’s flagship NHI medicines access programme, called CCMDD (Centralised Chronic Medicines Dispensing and Distribution) the majority, 76%, get HIV medication. In 2019, 24% are on NCDs medication alone. Getting CCMDD right for people with NCDs is absolutely critical and so far only those with hypertension are cracking it. What do you think?
So before #COVID19 continued access to medicines for NCDs was difficult and the pandemic just made it worse. So if you take HIV medications, ARVs, then you get access and access to remote pickup. Thus avoiding the risk of COVID-19 infection and possible death.
This PowerPoint Presentation is by National Department of Health’s Maggie Munsamy NHI Technical specialist and head of CCMDD. It was part of the Webinar hosted by CANSA for Universal Health Coverage Day 2020.
Prescribed Minimum Benefits
[vc_row][vc_column][vc_column_text]
Background
The Council for Medical Schemes (CMS) is embarking on a process to review the Prescribed Minimum Benefits (PMBs). In terms of the Medical Schemes Act 131 of 1998, the PMBs are subject to review after every two years to address issues relating to:
(i) inconsistencies or flaws in the current regulations;
(ii) the cost-effectiveness of health technologies or interventions;
(iii) consistency with developments in the health policy; and
(iv) the impact on medical scheme viability and its affordability on members[/vc_column_text][/vc_column][/vc_row]
Case For Patent Law Reform
MSF FTPL report-FINAL VERSION
In this report, we present nine case studies that demonstrate how
systemic shortcomings in South Africa’s patent laws negatively
impact on access to medicines to treat a wide range of diseases in
both the public and private sectors.
The case studies illustrate how a flawed system can allow
pharmaceutical companies to prolong their monopoly periods in
South Africa for years – and sometimes even decades – after their
patent protections have expired in other parts of the world, to the
detriment of millions of patients.
To prolong their periods of patent protection, companies
commonly apply for multiple patents on individual medicines
over time – a tactic known as evergreening. Due to shortcomings
in South Africa’s laws – namely, a lack of examination for patent
applications – ‘evergreening’ occurs frequently.